1.00Open0.88Pre Close6 Volume169 Open Interest15.00Strike Price475.00Turnover87.93%IV12.68%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.3027Delta0.1009Gamma21.76Leverage Ratio-0.0280Theta-0.0030Rho-6.59Eff Leverage0.0138Vega
Grail Stock Discussion
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet